Compare DMRC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMRC | SGMT |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 169.4M |
| IPO Year | 2008 | 2021 |
| Metric | DMRC | SGMT |
|---|---|---|
| Price | $9.48 | $6.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $26.13 |
| AVG Volume (30 Days) | 276.6K | ★ 783.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,213,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.69 | N/A |
| 52 Week Low | $4.07 | $4.50 |
| 52 Week High | $17.47 | $11.41 |
| Indicator | DMRC | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 49.26 |
| Support Level | $9.52 | $6.27 |
| Resistance Level | $10.31 | $7.20 |
| Average True Range (ATR) | 1.26 | 0.33 |
| MACD | -0.68 | -0.03 |
| Stochastic Oscillator | 3.78 | 41.88 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.